|
The FDA
-cleared capability for the Transonic Flow-QC Hemodialysis Monitor comes at a time when the
devastating effects of cardiovascular disease in the ESRD population is gaining increased recognition. As the
leading cause of ESRD morbidity and mortality (10 to 20 times the rate of the general population), cardiovascular
disease has reached epidemic proportions within the ESRD population.
Transonic Cardiac Function
(Flow-QC) Monitoring provides clinicians with a way to integrate cardiac function studies into a clinic's treatment protocols,
thereby forestalling the consequences of CVD.
Flow-QC Monitoring Immediately identifies Dangerously high and prolonged levels of access
flow which places abnormal stress on the heart and can possibly cause cardiomegaly and heart failure.
Dangerously low cardiac output which places patients at high risk for cardiovascular complications and failure.
- Dramatic decrease in Cardiac Index during
hemodialysis to dangerously low levels due to inaccurate dry weight estimation and/or inadequate medication.
- Dangerous decrease in Central Blood
Volume during dialysis that may portend hypotensive episodes.
Cardiac Output is measured
using Transonic Systems' proprietary ultrasound indicator dilution method. Cardiac Output and the derived parameters, Cardiac Index, Peripheral Resistance and Central Blood Volume give an on-site cardiac assessment for possible compromised Cardiac Function.
How It Works!
With dialysis lines
in normal position, 30 ml of 0.9% NaCl (Vv) is injected into the venous line. After the indicator traverses the heart and lung, the
concentration curve in the arterial line is recorded as shown by the diagram below. Cardiac output is calculated from the area of the
concentration curve by the classic equation: 
FDA Clears Cardiac Output measurements with the Transonic HD01 Flow-QC Hemodialysis Monitor. |
